Skip to Content
Merck

M005

S-(+)-Deprenyl hydrochloride

solid

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C13H17N · HCl
CAS Number:
Molecular Weight:
223.74
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


form

solid

optical activity

[α]24/D +11.84°, c = 0.1 in H2O(lit.)

color

white

solubility

H2O: soluble

SMILES string

Cl.C[C@@H](Cc1ccccc1)N(C)CC#C

Biochem/physiol Actions

Less active enantiomer of deprenyl.


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



J W Tetrud et al.
Science (New York, N.Y.), 245(4917), 519-522 (1989-08-04)
The effects of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin that produces the symptoms of Parkinson's disease, can be fully prevented in experimental animals by inhibiting monoamine oxidase B. On the basis of this observation, a double-blind, placebo-controlled study in patients with early
R E Heikkila et al.
Nature, 311(5985), 467-469 (1984-10-04)
1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) causes degeneration of the dopaminergic nigrostriatal pathway in several animal species, including humans, monkeys and mice. Changes observed after MPTP administration include marked decrements in the neostriatal content of dopamine and its major metabolites, dihydroxyphenylacetic acid and homovanillic
Jorge A Zavala et al.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 19(9), 1298-1299 (2012-06-23)
Pramipexole is a non-ergot dopamine agonist that is used frequently as a single therapy or in combination for the management of Parkinson's disease. Common side effects are daytime drowsiness, hypotension, hallucinations and compulsive behaviour. We describe a patient who developed